Esperion to Join ARCHIMED in $1.1B Cash Takeover with Milestone Upside
Esperion Therapeutics will be acquired by ARCHIMED for up to $1.1 billion in equity value, with shareholders receiving $3.16 per share in cash plus a non-tradeable contingent value right worth up to $100 million in milestone payments tied to future net sales of Esperion's bempedoic acid products (NEXLETOL/NEXLIZET) and bumetanide products (ENBUMYST). The deal, which includes a 58% premium to Esperion’s pre-announcement close, would privatize the company and is expected to close in Q3 2026 subject to shareholder and regulatory approvals; debt financing is provided by Pharmakon Advisors, and the board has unanimously approved the transaction.